Polymorphic Transporters and Platinum Pharmacodynamics

被引:54
作者
Sprowl, Jason A. [1 ]
Ness, Rachel A. [1 ]
Sparreboom, Alex [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
基金
美国国家卫生研究院;
关键词
solute carriers; cisplatin; carboplatin; oxaliplatin; drug disposition; SNPs; pharmacodynamics; ORGANIC CATION TRANSPORTERS; CISPLATIN-INDUCED NEPHROTOXICITY; CELL LUNG-CANCER; ADENOSINE-TRIPHOSPHATASE ATP7B; MULTIDRUG-RESISTANCE PROTEIN; TOXIN EXTRUSION MATE1; COPPER TRANSPORTER; ANION TRANSPORTER; HUMAN-KIDNEY; GENETIC POLYMORPHISMS;
D O I
10.2133/dmpk.DMPK-12-RV-073
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Several solute carriers and ATP-binding cassette transporters have been implicated in the influx or efflux of platinum-based chemotherapeutic agents such as cisplatin, carboplatin, and oxaliplatin. Given that many of these proteins are highly polymorphic, the genetic status of these proteins could be an important contributor to the extensive interindividual pharmacokinetic variability associated with the clinical use of these agents. In this review article, we provide an updated overview of the various transporters that have shown promise in animal models or patient populations in facilitating the movement of platinum-based agents across cell membranes, and how their function is associated with drug disposition or pharmacodynamic effects.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 128 条
[31]   Update on new drugs in small cell lung cancer [J].
Horn, Leora ;
Castellanos, Emily Louise ;
Johnson, David H. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) :441-455
[32]   Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney [J].
Hosoyamada, M ;
Sekine, T ;
Kanai, Y ;
Endou, H .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1999, 276 (01) :F122-F128
[33]   Assessment of cisplatin-induced nephrotoxicity by microarray technology [J].
Huang, Q ;
Dunn, RT ;
Jayadev, S ;
DiSorbo, O ;
Pack, FD ;
Farr, SB ;
Stoll, RE ;
Blanchard, KT .
TOXICOLOGICAL SCIENCES, 2001, 63 (02) :196-207
[34]   FDA drug approval summaries: Oxaliplatin [J].
Ibrahim, A ;
Hirschfeld, S ;
Cohen, MH ;
Griebel, DJ ;
Williams, GA ;
Pazdur, R .
ONCOLOGIST, 2004, 9 (01) :8-12
[35]   Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue [J].
Ip, Virginia ;
Liu, Johnson J. ;
Mercer, Julian F. B. ;
McKeage, Mark J. .
MOLECULAR PAIN, 2010, 6
[36]   Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals [J].
Ishida, S ;
Lee, J ;
Thiele, DJ ;
Herskowitz, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) :14298-14302
[37]   Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events [J].
Iwata, Kazufumi ;
Aizawa, Keiji ;
Kamitsu, Saori ;
Jingami, Sachiko ;
Fukunaga, Eiko ;
Yoshida, Minoru ;
Yoshimura, Misato ;
Hamada, Akinobu ;
Saito, Hideyuki .
CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (06) :843-851
[38]  
JACOBS C, 1984, CANCER RES, V44, P3632
[39]  
JACOBS C, 1991, CANCER, V67, P1518, DOI 10.1002/1097-0142(19910315)67:6<1518::AID-CNCR2820670610>3.0.CO
[40]  
2-3